ÂÜŔňÂŇÂ×

The newest member of the executive leadership team, Joe Hazelton, was appointed Chief Business Officer in November 2021. Mr. Hazelton is responsible for global commercialization of Dyadic’s new and existing business initiatives, including corporate strategy, business and corporate development and licensing. His appointment reinforces Dyadic’s commitment to maximize the integration of the C1 platform across life sciences and pharma in addition to opportunities in other industries.

A recognized industry veteran, Joe brings over 20 years of pharmaceutical experience in key growth areas of product and business development, licensing, and commercialization. Mr. Hazelton began his career in 1998 with Novartis Pharmaceuticals Corporation, where he held leadership positions within the core functions of sales, marketing, market access, pricing, contracting, and strategic alliances for various retail and specialty pharmaceuticals across a broad spectrum of therapeutic areas and several blockbuster products. Prior to joining Dyadic, he served as Chief Operating Officer and Chief Commercial Officer for Charleston Laboratories Inc., responsible for the strategic management of Charleston’s product and portfolio management, alliance management, regulatory oversight, and global commercialization activities.